Skip to content

NIR Arthroscopic Fluorescence Angiography of Menisci

Intraoperative Arthroscopic Near-infrared Fluorescence Imaging of the Vascular Perfusion of the Meniscus in Patients Treated With Meniscal Repair

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05420974
Acronym
FLUORarth
Enrollment
20
Registered
2022-06-16
Start date
2022-09-01
Completion date
2023-10-31
Last updated
2022-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meniscus Rupture

Brief summary

This trial is an explorative single center, single-arm study to assess whether vascularization of the meniscus can be visualized intraoperatively using arthroscopic near-infrared (NIR) fluorescence using ICG during standard of care meniscal repair treatment.

Detailed description

The meniscal healing process is based on two fundamental principles: a solid primary fixation, and a well-functioning biological process of cicatrization, where the presence of vascularization is thought to play a major role. Intra-operative near infrared fluorescence angiography using Indocyanine Green (ICG) is a widely used method for operative assessment of vascularization. Fluorescence guided detection of the vascularity surrounding a meniscal tear could be of great value to predict meniscal healing after repair. This pilot study will explore the technical feasibility of intraoperative near-infrared fluorescence angiography of the meniscus in patients undergoing arthroscopic meniscal repair. Technical challenges for NIR fluorescence arthroscopy are the visibility of the vascular perfusion in microvessels in the dense meniscus, motion artifacts encountered with arthroscopy and wash in of ICG using a fluid irrigation system. The included patients will be subdivided in four equal subgroups in order to evaluate alteration of NIR fluorescence signal during arthroscopy in combination with a tourniquet and/or irrigation pump system.

Interventions

PROCEDURENIR fluorescence imaging of the vascular perfusion of the meniscus using ICG

NIR fluorescence imaging of vascular perfusion using the Arthrex NIR fluorescence scope and Indocyanin Green

Sponsors

Arthrex, Inc.
CollaboratorINDUSTRY
Diagnostic Green GmbH
CollaboratorINDUSTRY
Isala
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18 years or older; * Patients with on MRI confirmed Zone 1 meniscal tear * Patients with a clinical indication for arthroscopic meniscal repair * Before patient registration, written consent must be given according to ICH/GCP, national and local regulations.

Exclusion criteria

* Prior operative treatment of the ruptured meniscus * Any condition that in the opinion of the investigator could potentially jeopardize the health status of the patient. In specific, these conditions concern smoking, diabetes and being overweight. * Pregnancy * allergy to iodine, shellfish or ICG; * Psychological, familial sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial;

Design outcomes

Primary

MeasureTime frameDescription
NIR fluorescence of the meniscusFluorescence imaging will be performed from 0-10 minutes after injection of ICGDetection of fluorescence in the meniscus (yes/no), determined intra-operatively during the arthroscopy procedure using NIR fluorescence imaging and ICG.

Secondary

MeasureTime frameDescription
T startFluorescence imaging will be performed from 0-10 minutes after injection of ICGTime between injection of ICG and initial detection of the fluorescence signal in the meniscus (T start).
I maxFluorescence imaging will be performed from 0-10 minutes after injection of ICGMaximum fluorescence intensity (Imax) in the meniscus. Fluorescence intensity will be measured in arbitrary units as a mean of three different region of interests.
T max0-10 minutesTime to maximum intensity of the fluorescence signal
Baseline and End fluorescence intensityFluorescence imaging will be performed from 0-10 minutes after injection of ICGBaseline fluorescence intensity of the meniscus and the end fluorescence intensity in the meniscus
The ration between the maximum fluorescence intensity in the meniscus and the background fluorecence intensity.Fluorescence imaging will be performed from 0-10 minutes after injection of ICGThe fluorescence intensity is measured in arbitrary units as a mean of three region of interests.

Contacts

Primary ContactPieter B.A.A. van Driel, MD, PhD
p.b.a.a.van.driel@isala.nl003188 6245000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026